Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aeva Technologies Inc (AEVA)

Aeva Technologies Inc (AEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Aeva Announces Date for First Quarter 2023 Results and Conference Call

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced that it will report results for the first quarter 2023 after market close on Wednesday, May 10, 2023. Aeva...

AEVA : 3.94 (+7.07%)
Aeva Showcases 4D LiDAR at Auto Shanghai 2023

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced it will demonstrate its 4D LiDAR™ technology for the automotive industry at Auto Shanghai 2023 – the...

AEVA : 3.94 (+7.07%)
Aeva Reports Fourth Quarter and Full Year 2022 Results

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced its fourth quarter and full year 2022 results.

AEVA : 3.94 (+7.07%)
Aeva Announces Date for Fourth Quarter and Full Year 2022 Results and Conference Call

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced that it will report results for the fourth quarter and full year 2022 after market close on Wednesday,...

AEVA : 3.94 (+7.07%)
Aeva to Participate in Upcoming Investor Events

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced it will participate in the following upcoming investor events.

AEVA : 3.94 (+7.07%)
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Aeva, Inc. (AEVA) Investigation

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of InterPrivate Acquisition Corporation, which merged with Aeva, Inc. ("Aeva" or "the...

AEVA : 3.94 (+7.07%)
Aeva and Plus Showcase Next Generation Design for PlusDrive Highly Automated Trucking Solution with Aeries II 4D LiDAR

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, and Plus, a global provider of autonomous driving solutions, today announced the unveiling of a design for the next generation...

AEVA : 3.94 (+7.07%)
Aeva to Demonstrate 4D LiDAR Technology for Automated Driving and Industrial Applications at CES 2023

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, announced it will demonstrate its award-winning 4D LiDAR™ technology for the automotive industry and industrial applications...

AEVA : 3.94 (+7.07%)
Aeva Honored with CES 2023 Innovation Award

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced that its Aeries™ II sensor has been named a CES ® 2023 Innovation Awards Honoree . The prestigious...

AEVA : 3.94 (+7.07%)
TIME Magazine Recognizes Aeva Aeries II 4D LiDAR as a Best Invention of 2022

Aeva ® (NYSE: AEVA), a leader in next-generation sensing and perception systems, today announced that its Aeries™ II 4D LiDAR™ sensor has been named one of TIME’s Best Inventions of 2022.

AEVA : 3.94 (+7.07%)

Barchart Exclusives

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy
Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a valuation a third cheaper than competitor, Eli Lilly. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar